The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Estimating the world cancer burden: Globocan 2000
Open accessAbstract
Describing the distribution of disease between different populations and over time has been a highly successful way of devising hypotheses about causation and for quantifying the potential for preventive activities.1 Statistical data are also essential components of disease surveillance programs. These play a critical role in the development and implementation of health policy, through identification of health problems, decisions on priorities for preventive and curative programs and evaluation of outcomes of programs of prevention, early detection/screening and treatment in relation to resource inputs. Over the last 12 years, a series of estimates of the global burden of cancer have been published in the International Journal of Cancer.2-6 The methods have evolved and been refined, but basically they rely upon the best available data on cancer incidence and/or mortality at country level to build up the global picture. The results are more or less accurate for different countries, depending on the extent and accuracy of locally available data. This "data-based" approach is rather different from the modeling method used in other estimates.7-10 Essentially, these use sets of regression models, which predict cause-specific mortality rates of different populations from the corresponding all-cause mortality.11 The constants of the regression equations derive from datasets with different overall mortality rates (often including historic data from western countries). Cancer deaths are then subdivided into the different cancer types, according to the best available information on relative frequencies. GLOBOCAN 2000 updates the previously published data-based global estimates of incidence, mortality and prevalence to the year 2000.12 The data sources that have been used to build up the global estimates are as follows. Incidence, the number of new cases occurring, can be expressed as the annual number of cases (the volume of new patients presenting for treatment) or as a rate per 100,000 persons per year. Incidence data are produced by population-based cancer registries.13 Registries may cover national populations or, more often, certain regions. In developing countries in particular, coverage is often confined to the capital city and its environs. It was estimated that, in 1990, about 18% of the world population were covered by registries, 64% of developed countries and 5% of developing countries, although the situation is improving each year. The most recent volume of "Cancer Incidence in Five Continents" (CI5) contains comparable incidence information from 150 registries in 50 countries, primarily over the period 1988–1992.14 Survival statistics are also produced by cancer registries by the follow-up of registered cancer cases. Population-based figures are published by registries in many developed countries, for example, the SEER program covering 10% of the U.S. population15 and the EUROCARE II project, including 17 countries of Europe.16 Survival data from populations of China, the Philippines, Thailand, India and Cuba have been published by Sankaranarayanan et al.17 Mortality is the number of deaths occurring and the mortality rate the number of deaths per 100,000 persons per year. It is the product of incidence and fatality (the inverse of survival) of a given cancer. Mortality rates measure the average risk to the population of dying from a specific cancer, while fatality (1-survival) represents the probability that an individual with cancer will die from it. Mortality data are derived from vital registration systems, where the fact and "underlying" cause of death are certified, usually by a medical practitioner. Their great advantage is comprehensive coverage and availability. By 1990, about 42% of the world population was covered by vital registration systems producing mortality statistics on cancer. Not all are, however, of the same quality in all countries. National-level statistics are collated and made available by the World Health Organiztion (http://www-dep.iarc.fr/dataava/globocan/who.htm), although for some countries coverage of the population is manifestly incomplete (so that the so-called mortality rates produced are implausibly low) and in others, quality of cause of death information is poor. Frequency data, e.g., case series from hospitals and pathology laboratories, provide an indication of the relative importance of different cancers in a country or region in the absence of a population-based registry and mortality statistics. There are problems in extrapolating the results to the general population, since such series are subject to various forms of selection bias. Such data are generally published locally or in journal articles, although a few compendia are available.18, 19 Prevalence is the proportion of a population that has the disease at a given point in time.20 For many diseases (e.g., hypertension, diabetes), prevalence usefully describes the number of individuals requiring care. For ca
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,781
Cancer Incidence in Five Continents
(1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,501
Higgins, S. M. F., Macken, A. P., Cullen, W., Saunders, J., Dunne, C. P., & O’Gorman, C. S. (2013) · PubMed · doi:10.34961/9953 · Cited by 4,805
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492
Estimates of the worldwide incidence of 25 major cancers in 1990
Parkin, Pisani, P., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990315)80:6<827::aid-ijc6>3.0.co;2-p · Cited by 2,037
Self-citationEstimates of the worldwide incidence of eighteen major cancers in 1985
Parkin, D. M., Pisani, P., & Ferlay, J. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540413 · Cited by 1,638
Self-citationQuantifying the burden of disease: the technical basis for disability-adjusted life years.
Murray, C. J. L. (1994) · Europe PMC (PubMed Central) · Cited by 1,581
Globocan 2000 : cancer incidence, mortality and prevalence worldwide
Ferlay, J., Pisani, P., & Parkin, D. M. (2001) · Medical Entomology and Zoology · Cited by 1,579
Self-citationEstimates of the worldwide mortality from 25 cancers in 1990
Pisani, P., Parkin, D. M., Bray, F., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990924)83:1<18::aid-ijc5>3.0.co;2-m · Cited by 1,549
Self-citationEstimates of the worldwide frequency of sixteen major cancers in 1980
Parkin, D. M., Läärä, E., & Muir, C. S. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410205 · Cited by 1,047
Self-citation
Cited by
Items 101–132 of 132
Habib, S. H. M., Makpol, S., Hamid, N. A. A., Das, S., Ngah, W. Z. W., & Yusof, Y. A. M. (2008) · Clinics · doi:10.1590/s1807-59322008000600017 · Cited by 283
Le Chevalier, T., Scagliotti, G., Natale, R., Danson, S., Rosell, R., Stahel, R., Thomas, P., Rudd, R. M., Vansteenkiste, J., Thatcher, N., et al. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2004.10.014 · Cited by 277
Bipat, S., Phoa, S. S. K. S., van Delden, O. M., Bossuyt, P. M. M., Gouma, D. J., Lam??ris, J. S., & Stoker, J. (2005) · Journal of Computer Assisted Tomography · doi:10.1097/01.rct.0000164513.23407.b3 · Cited by 272
Meta‐analysis of social inequality and the risk of cervical cancer
Parikh, S., Brennan, P., & Boffetta, P. (2003) · International Journal of Cancer · doi:10.1002/ijc.11141 · Cited by 272
Wang, W. H. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg106 · Cited by 269
Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T‐regulatory cells†‡
Unitt, E., Rushbrook, S. M., Marshall, A., Davies, S., Gibbs, P., Morris, L. S., Coleman, N., & Alexander, G. J. M. (2005) · Hepatology · doi:10.1002/hep.20644 · Cited by 267
International Collaboration of Epidemiological Studies of Cervical Cancer (2006) · International Journal of Cancer · doi:10.1002/ijc.21953 · Cited by 266
The multitude and diversity of environmental carcinogens
Belpomme, D., Irigaray, P., Hardell, L., Clapp, R., Montagnier, L., Epstein, S., & Sasco, A. J. (2007) · Environmental Research · doi:10.1016/j.envres.2007.07.002 · Cited by 261
Aflatoxin B1-induced DNA damage and its repair
Bedard, L. L., & Massey, T. E. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.11.018 · Cited by 261
Rotating Night-Shift Work and the Risk of Breast Cancer in the Nurses' Health Studies
Wegrzyn, L. R., Tamimi, R. M., Rosner, B. A., Brown, S. B., Stevens, R. G., Eliassen, A. H., Laden, F., Willett, W. C., Hankinson, S. E., & Schernhammer, E. S. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx140 · Cited by 258
Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?
Zhu, A. X. (2006) · The Oncologist · doi:10.1634/theoncologist.11-7-790 · Cited by 260
An Overview of Cancer Treatment Modalities
Abbas, Z., & Rehman, S. (2018) · Neoplasm · doi:10.5772/intechopen.76558 · Cited by 258
Unitt, E., Marshall, A., Gelson, W., Rushbrook, S. M., Davies, S., Vowler, S. L., Morris, L. S., Coleman, N., & Alexander, G. J. M. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.12.027 · Cited by 257
Gender Disparity of Hepatocellular Carcinoma: The Roles of Sex Hormones
Yeh, S.-H., & Chen, P.-J. (2010) · Oncology · doi:10.1159/000315247 · Cited by 256
Giannelli, G., Bergamini, C., Fransvea, E., Sgarra, C., & Antonaci, S. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.09.055 · Cited by 252
Global co-distribution of light at night (LAN) and cancers of prostate, colon, and lung in men
Kloog, I., Haim, A., Stevens, R. G., & Portnov, B. A. (2009) · Chronobiology International · doi:10.1080/07420520802694020 · Cited by 215
Pimentel-Nunes, P., Dinis-Ribeiro, M., Soares, J., Marcos-Pinto, R., Santos, C., Rolanda, C., Bastos, R., Areia, M., Afonso, L., Bergman, J., et al. (2012) · Endoscopy · doi:10.1055/s-0031-1291537 · Cited by 166
Nighttime light level co-distributes with breast cancer incidence worldwide
Kloog, I., Stevens, R. G., Haim, A., & Portnov, B. A. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9624-4 · Cited by 159
Ahern, R. M., Lozano, R., Naghavi, M., Foreman, K., Gakidou, E., & Murray, C. J. (2011) · Population Health Metrics · doi:10.1186/1478-7954-9-8 · Cited by 106
Shimoda, M., Takahashi, M., Yoshimoto, T., Kono, T., Ikai, I., & Kubo, H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0712 · Cited by 106
Use of mobile telemedicine for cervical cancer screening
Quinley, K. E., Gormley, R. H., Ratcliffe, S. J., Shih, T., Szep, Z., Steiner, A., Ramogola-Masire, D., & Kovarik, C. L. (2011) · Journal of Telemedicine and Telecare · doi:10.1258/jtt.2011.101008 · Cited by 92
Diagnostic strategies for postmenopausal bleeding.
Breijer, M. C., Timmermans, A., van Doorn, H. C., Mol, B. W. J., & Opmeer, B. C. (2010) · Obstetrics and Gynecology International · doi:10.1155/2010/850812 · Cited by 82
Rapid ratiometric biomarker detection with topically applied SERS nanoparticles
Wang, Y. "., Khan, A., Som, M., Wang, D., Chen, Y., Leigh, S. Y., Meza, D., McVeigh, P. Z., Wilson, B. C., & Liu, J. T. C. (2014) · TECHNOLOGY · doi:10.1142/s2339547814500125 · Cited by 74
Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers
Zhang, X., Gee, H., Rose, B., Lee, C. S., Clark, J., Elliott, M., Gamble, J. R., Cairns, M. J., Harris, A., Khoury, S., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2109-4 · Cited by 65
The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer
Gridelli, C., Rossi, A., & Maione, P. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.03.002 · Cited by 54
Lin, B.-R., Chang, C.-C., Chen, L.-R., Wu, M.-H., Wang, M.-Y., Kuo, I.-H., Chu, C.-Y., Chang, K.-J., Lee, P.-H., Chen, W.-J., et al. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0289 · Cited by 51
Afzal, M., Kazmi, I., Gupta, G., Rahman, M., Kimothi, V., & Anwar, F. (2012) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2012.05.012 · Cited by 45
Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis
Anupam, K. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i37.6041 · Cited by 45
Pichon-Riviere, A., Augustovski, F., Bardach, A., & Colantonio, L. (2011) · Value in Health · doi:10.1016/j.jval.2011.05.010 · Cited by 43
Yao, Y., Tao, H., Kim, J. J., Burkhead, B., Carloni, E., Gasbarrini, A., & Sepulveda, A. R. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700117 · Cited by 29
De La Cena, K. O. C., Ho, R. X.-Y., Amraei, R., Woolf, N., Tashjian, J. Y., Zhao, Q., Richards, S., Walker, J., Huang, J., Chitalia, V. C., et al. (2021) · The American Journal of Pathology · doi:10.1016/j.ajpath.2020.09.015 · Cited by 23
McLaughlin, J. M., Olivo-Marston, S., Vitolins, M. Z., Bittoni, M., Reeves, K. W., Degraffinreid, C. R., Schwartz, S. J., Clinton, S. K., & Paskett, E. D. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0329 · Cited by 22
Metadata
- Authors
- Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2001
- Volume
- 94
- Issue
- 2
- Pages
- 153-156
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2017352677
- Cited by
- 3,721
- References
- 25
- FWCI
- 29.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.